Glenmark Pharmaceuticals has informed about submission of media release titled, ‘Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)’, which is self explanatory.
The above information is a part of company’s filings submitted to BSE.